The latest price target for Novo Nordisk (NYSE:NVO) was reported by Cantor Fitzgerald on November 6, 2024. The analyst firm set a price target for $160.00 expecting NVO to rise to within 12 months (a possible 85.61% upside). 26 analyst firms have reported ratings in the last year.

The latest analyst rating for Novo Nordisk (NYSE:NVO) was provided by Cantor Fitzgerald, and Novo Nordisk reiterated their overweight rating.

The last upgrade for Novo Nordisk AS happened on June 7, 2022 when JP Morgan raised their price target to N/A. JP Morgan previously had a neutral for Novo Nordisk AS.

The last downgrade for Novo Nordisk AS happened on June 28, 2022 when UBS changed their price target from N/A to N/A for Novo Nordisk AS.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Novo Nordisk, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Novo Nordisk was filed on November 6, 2024 so you should expect the next rating to be made available sometime around November 6, 2025.

While ratings are subjective and will change, the latest Novo Nordisk (NVO) rating was a reiterated with a price target of $160.00 to $160.00. The current price Novo Nordisk (NVO) is trading at is $86.20, which is out of the analyst’s predicted range.